Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 11:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo i.m. injection Clear all
Completed Phase 3 Interventional Results available

Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia

NCT00590577
View directory record Official record
Conditions
Schizophrenia
Interventions
Paliperidone palmitate 25 mg eq., Paliperidone palmitate 150 mg eq., Placebo, Paliperidone palmitate 100 mg eq.
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
32
States / cities
Anaheim, California • Cerritos, California • Escondido, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Sep 15, 2026, 11:24 PM EDT
Completed Phase 3 Interventional Results available

Dysport® Adult Lower Limb Spasticity Study

NCT01249404
View directory record Official record
Conditions
Leg Spasticity
Interventions
Botulinum toxin type A, Placebo
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 80 Years
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
17
States / cities
Scottsdale, Arizona • Downey, California • Oxnard, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 15, 2026, 11:24 PM EDT
Completed Phase 3 Interventional Results available

Dysport® Pediatric Lower Limb Spasticity Study

NCT01249417
View directory record Official record
Conditions
Cerebral Palsy, Muscle Spasticity, Children
Interventions
Botulinum toxin type A, Placebo
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
2 Years to 17 Years
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
8
States / cities
Aurora, Colorado • Chicago, Illinois • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 15, 2026, 11:24 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines

NCT02236312
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxin Type A, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
8
States / cities
Birmingham, Alabama • Mobile, Alabama • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Sep 15, 2026, 11:24 PM EDT
Completed Phase 3 Interventional Results available

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II

NCT02677805
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxin A, Placebo, Botulinum Toxin A - Open Label
Drug
Lead sponsor
Croma-Pharma GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Encinitas, California • Aventura, Florida • Sarasota, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Sep 15, 2026, 11:24 PM EDT
Completed Phase 3 Interventional Results available

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)

NCT03985982
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxin A, Placebo
Drug
Lead sponsor
Croma-Pharma GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 15, 2026, 11:24 PM EDT
Completed Phase 2 Interventional

Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients

NCT01097096
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
CAD106, Placebo, Alum, MF59
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Up to 85 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Costa Mesa, California • Boulder, Colorado • Hollywood, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Sep 15, 2026, 11:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety of a New Oxime, MMB4 DIMETHANESULFONATE (DMS)

NCT02018250
View directory record Official record
Conditions
Safety and Efficacy
Interventions
MMB4 DMS, Placebo
Drug
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Sep 15, 2026, 11:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Impact of Estradiol Addback

NCT01862835
View directory record Official record
Conditions
Normal Healthy Volunteers
Interventions
Degarelix, Testosterone, Anastrozole, Estrogen patch
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
60 Years to 80 Years · Male only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Sep 15, 2026, 11:24 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder

NCT01193153
View directory record Official record
Conditions
Schizoaffective Disorder
Interventions
Placebo, paliperidone palmitate
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
28
States / cities
Garden Grove, California • Oakland, California • Oceanside, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2015 · Synced Sep 15, 2026, 11:24 PM EDT
Completed Phase 3 Interventional Results available

Dysport® Adult Upper Limb Spasticity

NCT01313299
View directory record Official record
Conditions
Nervous System Disorders
Interventions
Botulinum toxin type A, Placebo
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 80 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
15
States / cities
Downey, California • Fairfield, Connecticut • Boca Raton, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 15, 2026, 11:24 PM EDT
Completed Phase 1 Interventional

Drug Discrimination in Methadone-Maintained Humans Study 1

NCT00593463
View directory record Official record
Conditions
Drug Dependence
Interventions
Cycloserine, Diltiazem, Gabapentin, Isradipine, Naloxone, Nifedipine, Placebo, Saline, Verapamil
Drug · Device
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2011 · Synced Sep 15, 2026, 11:24 PM EDT
Completed Phase 1 Interventional

Drug Discrimination in Methadone-Maintained Humans Study 2

NCT00733239
View directory record Official record
Conditions
Opioid Dependence
Interventions
2-4 of the drugs listed below
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2012 · Synced Sep 15, 2026, 11:24 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients

NCT01356602
View directory record Official record
Conditions
Acute Gouty Arthritis
Interventions
Canakinumab pre-filled syringe, Canakinumab lyophilized powder, Triamcinolone Acetonide, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
69
States / cities
Anniston, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 62 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2014 · Synced Sep 15, 2026, 11:24 PM EDT
Completed Phase 1 Interventional

Drug Discrimination in Methadone-Maintained Humans Study 3

NCT01068847
View directory record Official record
Conditions
Drug Dependence
Interventions
2-4 of the drugs listed below
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2013 · Synced Sep 15, 2026, 11:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals

NCT01136356
View directory record Official record
Conditions
Opioid Abuse, Opioid Dependence
Interventions
buprenorphine, morphine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 15, 2026, 11:24 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

NCT02565511
View directory record Official record
Conditions
Alzheimers Disease
Interventions
CAD106 Immunotherapy, Placebo to CAD106, CNP520, Placebo to CNP520, Alum
Biological · Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years to 75 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
78
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Sep 15, 2026, 11:24 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I

NCT02677298
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxin A, Placebo
Drug
Lead sponsor
Croma-Pharma GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
784 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
9
States / cities
Birmingham, Alabama • Encino, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Sep 15, 2026, 11:24 PM EDT
Withdrawn Phase 2 Interventional

Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)

NCT00986960
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
repository corticotropin injection, Saline
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 15, 2026, 11:24 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

5-Alpha Reductase and Anabolic Effects of Testosterone

NCT00475501
View directory record Official record
Conditions
Male Hypogonadism, Muscle Atrophy, Sarcopenia, Benign Prostate Hypertrophy
Interventions
Testosterone Enanthate, Finasteride, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Sep 15, 2026, 11:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Testosterone-Driven Growth-Hormone (GH) Secretion in Aging Men

NCT00309855
View directory record Official record
Conditions
Aging
Interventions
Placebo, Testosterone, Anastrazole, Dutasteride
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 80 Years · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Sep 15, 2026, 11:24 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study in Healthy Adults to Evaluate the Safety and Immunogenicity of Different Doses of JNJ-63871860

NCT02546960
View directory record Official record
Conditions
Healthy
Interventions
ExPEC4V (4 : 4 : 4 : 4), ExPEC4V (4 : 4 : 4 : 8), ExPEC4V (8 : 8 : 8 : 8), ExPEC4V (8 : 8 : 8 : 16), ExPEC4V (16 : 16 : 16 : 16), Placebo
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
848 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
17
States / cities
Mesa, Arizona • Hollywood, Florida • Leesburg, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Sep 15, 2026, 11:24 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia

NCT00589914
View directory record Official record
Conditions
Schizophrenia
Interventions
RISPERDAL CONSTA, Paliperidone palmitate
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
1,221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
15
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Cerritos, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2014 · Synced Sep 15, 2026, 11:24 PM EDT
Completed Phase 2 Interventional Results available

Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients

NCT00798369
View directory record Official record
Conditions
Acute Gout
Interventions
Canakinumab, Triamcinolone acetonide
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
27
States / cities
Anniston, Alabama • Birmingham, Alabama • Buena Park, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2012 · Synced Sep 15, 2026, 11:24 PM EDT